Dr. Robert G. Bociek, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 261
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NE license 20918
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The Nebraska Medical Center Omaha, NE
- Bellevue Medical Center Bellevue, NE
- St Lukes Regional Medical Center Sioux City, IA
Medical groups
- Unmc Physicians (1,518 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 261
- Services billed
- 909
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 426 | 185 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 384 | 83 |
| Hospital discharge day management, 30 minutes or less | 44 | 39 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 21 | 20 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 20 | 19 |
| New patient office or other outpatient visit, 60-74 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Calquence (acalabrutinib maleate) | 127 |
| Acyclovir Other prescribers in Omaha, NE | 68 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Omaha, NE | 61 |
| Imbruvica (ibrutinib) | 61 |
| Prednisone Other prescribers in Omaha, NE | 38 |
| Brukinsa (zanubrutinib) | 34 |
| Allopurinol Other prescribers in Omaha, NE | 23 |
| Xarelto (rivaroxaban) Other prescribers in Omaha, NE | 22 |
| Revlimid (lenalidomide) | 21 |
| Ondansetron Odt (ondansetron) Other prescribers in Omaha, NE | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $44.92 in total to this clinician.
| Beone Medicines USA, Inc. | $44.92 |
|---|
| Food and Beverage | $44.92 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $278,815 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
Beone Medicines Ltd. · Active, not recruiting · NCT04170283 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
AbbVie Inc. · Active, not recruiting · NCT06191744 - A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT01712490
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.